Hybrid UV-Vis/MS Assay for Free Cysteine Determination in Monoclonal Antibodies

Significance of the topic

The presence and chemical state of cysteine residues in monoclonal antibodies (mAbs) strongly influence structural integrity, aggregation propensity, and biological function. Quantifying reactive (free) thiols and mapping their locations supports product quality control, comparability studies between innovator and biosimilar products, and rational design of antibody‑drug conjugates where controlled cysteine reactivity dictates conjugation efficiency and drug‑to‑antibody ratio (DAR). Combining a rapid spectrophotometric assay for overall thiol content with high‑resolution mass spectrometry (MS) for site identification yields complementary quantitative and structural information required in biopharma analytics.

Objectives and overview of the study

This application note demonstrates a hybrid workflow that:

• Quantifies free sulfhydryl groups in mAbs using Ellman's reagent (DTNB) and UV‑Vis absorbance at 412 nm measured on an Agilent Cary 3500 Multicell spectrophotometer, and
• Maps TNB (2‑nitro‑5‑thiobenzoic acid) labeling sites on heavy and light chains using high‑resolution Agilent 6545XT AdvanceBio LC/Q‑TOF MS following partial reduction.

The combined approach correlates a global thiol‑to‑protein ratio from UV‑Vis with chain‑ and glycoform‑resolved TNB labeling patterns from MS, providing both assay throughput and structural confidence.

Methodology

• Sample preparation: Rituximab innovator and biosimilar samples (10 mg/mL stock) were diluted to 5 mg/mL in 0.1 M sodium phosphate buffer (pH 8.0) with 1 mM EDTA. Partial reduction was performed by adding TCEP to 10 mmol/L and incubating 4 hours at room temperature. Controls without TCEP were processed in parallel. Samples were buffer‑exchanged and concentrated using 10 kDa MWCO spin columns and stored at −20 °C until analysis.
• Ellman’s (DTNB) assay: DTNB stock (~10 mM) was mixed with sample in reaction buffer (0.1 M sodium phosphate, pH 8.0, 1 mM EDTA), incubated ~15 minutes at room temperature, and absorbance measured at 412 nm. A multicell configuration enabled simultaneous measurement of multiple standards and samples. A cysteine standard series spanning 0.25–1.5 mM produced a linear calibration (acceptance R² ≥ 0.95; measured R² ≈ 0.999).
• Calculation: Free‑SH:protein molar ratios were calculated from the absorbance‑derived sulfhydryl concentration and the molar amount of antibody. The Ellman assay spectra showed an isosbestic point near 357 nm and a diagnostic TNB absorbance peak at 412 nm, useful for assay validation.
• LC/MS analysis: DTNB‑reacted, reduced samples were separated on a PLRP‑S reversed‑phase column (2.1 × 50 mm, 5 µm) using a water/ACN gradient with 0.1% formic acid, then analyzed by Agilent 6545XT AdvanceBio LC/Q‑TOF in positive ESI mode. Deconvolution and structural assignment used Agilent MassHunter BioConfirm and related software.

Used instrumentation

• Agilent Cary 3500 Multicell UV‑Vis Spectrophotometer with multicell ultra‑microvolume rectangular cells (10 mm pathlength, 70 µL fill, 50 µL sample) and Cary UV Workstation software v1.6.
• Agilent 1290 Infinity II Bio LC (high‑speed pump, multisampler, multicolumn thermostat) with Agilent PLRP‑S column (2.1 × 50 mm, 5 µm).
• Agilent 6545XT AdvanceBio LC/Q‑TOF (G6549AA) with Dual AJS ESI source; MassHunter acquisition v11.0 and BioConfirm v12.1 for data analysis.
• Common reagents and consumables: DTNB, L‑cysteine standards, TCEP, EDTA, LC/MS‑grade solvents, and 10 kDa MWCO centrifugal concentrators.

Main results and discussion

• Ellman quantification: The cysteine standard series yielded excellent linearity across 0.25–1.5 mM (reported R² ≈ 0.999). Using the calibration, native mAbs exhibited very low free‑SH:protein ratios (≈0.06–0.14 mol SH per mol antibody), consistent with intact disulfide bonding. Partially reduced samples showed substantially higher ratios (≈6.6–10.3), consistent with exposure of multiple cysteine residues after controlled reduction.
• Spectral validation: The full absorbance spectra of standards showed an isosbestic point near 357 nm and a clear absorbance peak at 412 nm, supporting assay specificity and stoichiometry between DTNB and free thiols.
• MS site mapping: Deconvoluted LC/Q‑TOF spectra revealed chain‑resolved TNB conjugation states and preserved intrachain disulfide bonds. Across innovator and biosimilar samples, MS reproducibly detected one TNB on the light chain and three TNBs on the heavy chain (per chain), consistent with four reactive cysteines per antibody half‑molecule; for intact antibodies this corresponds to eight reactive cysteines in the reduced state, aligning with UV‑Vis quantification.
• Glycoform resolution: The LC/Q‑TOF data resolved glycoforms (G0F, G1F, G2F) and showed TNB‑modified species across these glycoforms, demonstrating the method's ability to simultaneously report on glycosylation heterogeneity and cysteine labeling.
• Interpretation: The combined dataset validates that controlled TCEP reduction exposes a defined subset of interchain disulfide bonds while preserving intrachain linkages; the DTNB assay gives a rapid global measure of reactive thiols while MS provides chain‑ and site‑specific confirmation, reducing ambiguity in interpretation of spectroscopic results.

Benefits and practical applications of the method

• Complementary data: Fast, high‑throughput UV‑Vis quantitation combined with structural MS confirmation balances throughput and molecular detail—suitable for routine QC and investigational studies.
• Comparability and biosimilar assessment: The workflow sensitively distinguishes native versus partially reduced thiol states and can compare innovator and biosimilar lots for parity in cysteine accessibility and reduction susceptibility.
• ADC development: Mapping reactive cysteines under controlled reduction conditions informs conjugation site selection and expected DAR distributions for cysteine‑linked ADCs.
• Method robustness: Multicell UV‑Vis measurement increases throughput and repeatability; LC/Q‑TOF provides high mass accuracy and glycoform resolution to support structural assignments.

Future trends and potential applications

• Higher throughput and automation: Integration of sample automation and online derivatization could accelerate routine thiol monitoring in manufacturing workflows.
• Native and middle‑down MS: Native MS and middle‑down (subunit) approaches may provide complementary information on intact disulfide connectivity and noncovalent structure without extensive reduction/denaturation.
• Peptide‑level mapping and quantitation: Combining DTNB labeling with peptide mapping would allow site‑occupancy quantitation at the residue level and improved detection of low‑abundance modification variants.
• Alternative chemistries and probes: Development of other thiol‑reactive chromophores or florescent tags with improved sensitivity or orthogonal detectability may expand dynamic range and enable multiplexing.
• Regulatory and QC standardization: Establishing harmonized acceptance criteria and controls for thiol assays will support comparability studies and product release testing across platforms.

Conclusion

The hybrid UV‑Vis (Ellman) plus LC/Q‑TOF MS workflow provides a practical and analytically robust strategy to quantify reactive cysteines and to assign their locations in monoclonal antibodies. The Cary 3500 multicell UV‑Vis assay offers rapid, linear quantitation of free thiols with good throughput, while high‑resolution LC/Q‑TOF MS confirms the number and chain localization of TNB labels and resolves glycoforms. Together the techniques deliver complementary quantitative and structural insight useful for QC, comparability, and ADC development, and the approach is extensible to other cysteine‑containing biologics.

References

1. Liu H., May K. Disulfide Bond Structures of IgG Molecules: Structural Variations, Chemical Modifications and Possible Impacts to Stability and Biological Function. MAbs 2012, 4(1), 17–23.
2. Banks D. D., Gadgil H. S., Pipes G. D., et al. Removal of Cysteinylation from an Unpaired Sulfhydryl in the Variable Region of a Recombinant Monoclonal IgG1 Antibody Improves Homogeneity, Stability, and Biological Activity. J. Pharm. Sci. 2008, 97(2), 775–790.
3. Trexler‑Schmidt M., Sargis S., Chiu J., et al. Identification and Prevention of Antibody Disulfide Bond Reduction During Cell Culture Manufacturing. Biotechnol. Bioeng. 2010, 106(3), 452–461.
4. Furuki K., Toyo'oka T. Determination of Thiol‑to‑Protein Ratio and Drug‑to‑Antibody Ratio by In‑Line Size Exclusion Chromatography with Post‑Column Reaction. Anal. Biochem. 2017, 527, 33–44.
5. Abdollahpour‑Alitappeh M., Lotfinia M., Razavi‑Vakhshourpour S., et al. Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates. Iran Biomed. J. 2017, 21(4), 270–274.